$1b deal here were come, page-82

Coolstocks, I hope you are right about March.

The last presentations gave us a hint has to what has to happen for that to occur if the deal is partnering on one of our programs.

For a start we know that the HCV/HBV programs are off the table. Secondly, we know that for big pharma to take an interest in one of our other programs peer reviewed scientific data needs to be in the public domain. So far we have not heard about any such publications. It is possible that there is a deal waiting in the wings that is contingent on good scientific data and that is what we have to hope for. So, I agree we have to continue to be patient but that patience may need to stretch a little longer than March.

Meanwhile, the Appendix 4C should be out on Thursday and the Half Yearly Report should be out before the end of Feb. These should give us some understanding of where we are.